Methods and compositions for targeting compounds to the central nervous system

• US 6,399,575 B1
• Filed: 11/10/1999
• Issued: 06/04/2002
• Est. Priority Date: 11/10/1998
• Status: Expired due to Fees

• Current Assignee: Auburn University
• Original Assignee: Auburn University
• Inventors: Baker, Henry J., Samoilova, Tatiana I., Smith, Bruce F.
• Primary Examiner(s): Kunz, Gary L.
• Assistant Examiner(s): Gucker, Stephen
• Application Number:
  US09/438,150
• Time in Patent Office: 937 Days
• Field of Search: 530/326-329, 514/13-16
• US Class Current: 514/17.7
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids

Abstract

Compositions for use in targeting therapies to central nervous system (CNS) cells are provided. The compositions comprise peptides which are capable of binding CNS cells in vivo.

Claims

1. An isolated brain-specific peptide capable of binding to brain cells in vivo, wherein said peptide consists of the amino acid sequence set forth in SEQ ID NO:

1.

2. An isolated peptide consisting of the amino acid sequence set forth in SEQ ID NO:

1 coupled to a compound.

3. The peptide of claim 2, wherein said compound is selected from the group consisting of drugs, proteins, and nucleic acids.

4. The peptide of claim 2, wherein said compound is useful for treating a brain disorder.